Search Results - "Jensen, Ivar"

Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients by Malone, Daniel C., Dean, Rebecca, Arjunji, Ramesh, Jensen, Ivar, Cyr, Phil, Miller, Beckley, Maru, Benit, Sproule, Douglas M., Feltner, Douglas E., Dabbous, Omar

“…Background: Spinal muscular atrophy type 1 (SMA1) is a devastating genetic disease for which gene-replacement therapy may bring substantial survival and…”
Get full text

Evaluating cost benefits of combination therapies for advanced melanoma by Jensen, Ivar S, Zacherle, Emily, Blanchette, Christopher M, Zhang, Jie, Yin, Wes

“…Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the…”
Get full text

Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective by Jensen, Ivar S., Wu, Elizabeth, Cyr, Philip L., Claussen, Marc, Winkler, Thomas, Salahuddin, Khalid, Prats, Jayne, Mahaffey, Kenneth W., Gibson, Charles Michael, Steg, Philippe Gabriel, Stone, Gregg W., Bhatt, Deepak L.

“…Objectives The objective of this study was to evaluate a US hospital’s cost implications and outcomes of cangrelor use in percutaneous coronary intervention…”
Get full text

Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives by Hathway, Joanne M, Miller-Wilson, Lesley-Ann, Jensen, Ivar S, Ozbay, Burak, Regan, Catherine, Jena, Anupam B, Weinstein, Milton C, Parks, Philip D

“…To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), and expanded…”
Get more information

Exploring the Cost-Effectiveness of Newborn Screening for Metachromatic Leukodystrophy (MLD) in the UK by Bean, Karen, Jones, Simon A, Chakrapani, Anupam, Vijay, Suresh, Wu, Teresa, Church, Heather, Chanson, Charlotte, Olaye, Andrew, Miller, Beckley, Jensen, Ivar, Pang, Francis

“…Metachromatic leukodystrophy (MLD) is a fatal inherited lysosomal storage disease that can be detected through newborn bloodspot screening. The feasibility of…”
Get full text

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER) by Dean, Rebecca, Jensen, Ivar, Cyr, Phil, Miller, Beckley, Maru, Benit, Sproule, Douglas M., Feltner, Douglas E., Wiesner, Thomas, Malone, Daniel C., Bischof, Matthias, Toro, Walter, Dabbous, Omar

“…Background: Recent cost-utility analysis (CUA) models for onasemnogene abeparvovec (Zolgensma®, formerly AVXS-101) in spinal muscular atrophy type 1 (SMA1)…”
Get full text

The health economic impact of varying levels of adherence to colorectal screening on providers and payers by Hathway, Joanne M, Miller-Wilson, Lesley-Ann, Yao, Weiyu, Jensen, Ivar S, Weinstein, Milton C, Parks, Philip D

“…To examine the impact of increasing multi-target stool DNA test (mt-sDNA [Cologuard]) utilization for colorectal cancer (CRC) screening in cohorts aged 50-75…”
Get more information

Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis by Jensen, Ivar S, Wu, Elizabeth, Fan, Weihong, Lodise, Thomas P, Nicolau, David P, Dufour, Scott, Cyr, Philip L, Sulham, Katherine A

“…It is estimated that acute bacterial skin and skin structure infections (ABSSSI) account for nearly 10% of hospital admissions and 3.4-3.8 million emergency…”
Get full text

Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes by Jensen, Ivar S, Wu, Elizabeth, Sacks, Naomi C, Cyr, Philip L, Chung, Karen C

“…Current national estimates for acute myelogenous leukemia (AML) indicate this disease accounts for 1.1% of new cancer diagnoses and 1.8% of cancer deaths in…”
Get full text

The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population by Hathway, Joanne M, Miller-Wilson, Lesley-Ann, Sharma, Abhishek, Jensen, Ivar S, Yao, Weiyu, Raza, Sajjad, Parks, Philip D, Weinstein, Milton C

“…Background: In the United States (US), colorectal cancer (CRC) is the second leading cause of cancer-related deaths. With the majority of the US population…”
Get full text

Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis by Jensen, Ivar S., Lodise, Thomas P., Fan, Weihong, Wu, Chining, Cyr, Philip L., Nicolau, David P, DuFour, Scott, Sulham, Katherine A.

“…Background and Objective Nearly 10 % of all US hospital admissions are attributed to acute bacterial skin and skin structure infections (ABSSSIs). While most…”
Get full text

Cost-consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer by Jensen, Ivar S, Hathway, Joanne, Cyr, Philip, Gauden, David, Gardiner, Peter

“…Background: Current detection methodologies are often unable to identify the location and extent of recurrent prostate cancer (PCa) leading potentially to…”
Get full text

The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US by Pang, Francis, Dean, Rebecca, Jensen, Ivar, Bean, Karen, Fields, Christopher, Miller, Beckley

Get full text

The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy in France by Pang, Francis, Dean, Rebecca, Jensen, Ivar, Tehard, Bertrand, Roze, Stephane, Olaye, Andrew, Bean, Karen, Miller, Beck

Get full text

Economic Model Shows That Guideline Recommended Testing of Patients with Early Symptoms of Myeloma Results in Improved Patient Outcomes and Decreased Hospital Costs by Wu, Elizabeth, Jensen, Ivar S, Cyr, Philip, Kisner, Harold

“…Introduction : Multiple myeloma (MM) is a hematologic cancer of the plasma cells, which are found in the bone marrow. The early symptoms of MM are often vague…”
Get full text

Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements by Alexander, W. Allan, Jensen, Ivar, Hathway, Joanne, Srivastava, Krutika, Cyr, Philip, Sidonio, Robert F, Batt, Katharine

Get full text

Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective by Jensen, Ivar S, Wu, Elizabeth, Sacks, Naomi, Cyr, Philip, Chung, Karen

“…AML is a rapidly progressing and life-threatening blood cancer that disproportionately affects older adults. The treatment paradigm in AML has seen little…”
Get full text

Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome by Yao, Weiyu, Jensen, Ivar, Claussen, Marc, Dandurand, Kristen, Buffington, Brandy, Fuentes, Daniel, Mikhael, Michel

“…OBJECTIVETo quantify the effect of early rescue surfactant administration techniques for preterm infants with respiratory distress syndrome (RDS) from a health…”
Get full text

Cost-consequence analysis of 18 F-fluciclovine for the staging of recurrent prostate cancer by Jensen, Ivar S, Hathway, Joanne, Cyr, Philip, Gauden, David, Gardiner, Peter

“…: Current detection methodologies are often unable to identify the location and extent of recurrent prostate cancer (PCa) leading potentially to 'futile' local…”
Get full text

Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements by Alexander, W Allan, Jensen, Ivar, Hathway, Joanne, Srivastava, Krutika, Cyr, Philip, Sidonio, Jr, Robert F, Batt, Katharine

“…A mainstay of treatment in patients with hemophilia with inhibitors (PWIs) is the use of a recombinant factor VIIa (rFVIIa) bypassing agent. A new rFVIIa…”
Get more information